Innovative nitric oxide delivery device company predicting vibrant market for its next-generation products
SALT LAKE CITY, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB:NUMD), a medical device leader developing new nitric oxide delivery technology along with innovative applications in the medical field, anticipants that recent patent rulings have created a very favorable market environment for Nu-Med Plus nitric oxide delivery products.
A Federal Circuit Court ruling in May invalidated the majority of a patent for a dominant nitric oxide producer, which allowed a single company to sell nitric oxide gas for medical use. Now other gas supply companies are expected to enter and expand the medical nitric oxide market.
With the monopoly broken the resulting market expansion will result in a greater demand for Nu-Med Plus delivery devices explains Jeff Robins, CEO of Nu-Med Plus. Robins said, “With large gas supply companies entering the medical nitric oxide market we are ideally positioned to partner with them to sell our delivery systems with their gases. The result is a win-win situation for patients and business. As activity in the medical nitric oxide market increases, treatment costs will go down.”
Inhaled Nitric oxide is a medically essential gas. Currently patients suffering from neonatal hypoxia-ischemia, chronic obstructive pulmonary disease (COPD) and other pulmonary problems utilize this critical (INO) inhaled nitric oxide therapy. Future applications for a variety of other diseases and complications are currently being investigated. Nu-Med Plus nitric oxide delivery products are designed to offer portability, a new level of precision, and offer a cost-effective method for administrating exacting therapeutic quantities of nitric oxide to patients for a variety of treatments.
Nu-Med Plus, Inc. is a medical device company created to develop new nitric oxide delivery technology and focus applications on high growth-potential markets where a clearly defined need has been recognized by the medical community. Initial research and product development has been in the delivery of (INO)inhaled nitric oxide gas for therapeutic use.
Media Contact: eric@s2spr.com
About Nu-Med Plus, Inc.: Nu-Med Plus, Inc. founded in 2011 is a medical device development company created to explore medical applications of newly developed nitric oxide technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.
Forward-Looking Statements: Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.